Skip to content

Our Team

Werewolf Leadership
Scientific Advisory Board
Board of Directors
Investors

Werewolf Leadership

Werewolf Therapeutics is backed by leading life science investors and led by an experienced team with a proven track record of developing novel medicines for the treatment of cancer.
Dan Hicklin, Ph.D.
President, Chief Executive Officer and Board member
Dan Hicklin, Ph.D.
President, Chief Executive Officer and Board member

Dr. Dan Hicklin is an accomplished cancer researcher and biopharmaceutical executive with over three decades of oncology drug development experience. Currently, Dr. Hicklin holds a number of executive positions:

  • Executive Partner at MPM Capital
  • Founder and CEO of Werewolf Therapeutics
  • President of Trieza Therapeutics

Prior to his current positions, he founded Potenza Therapeutics (acquired by Astellas Pharma) where he was President and CEO, served as President and CSO of CoStim Pharmaceuticals (acquired by Novartis), and was on the board of directors of Harpoon Therapeutics and the scientific advisory board of Oncorus.

Earlier in his career, Dr. Hicklin held several positions at Merck Research Laboratories (formerly the Schering-Plough Research Institute), including leading their Biologics Strategy for Oncology and the Immuno-Modulation Discovery team. In these roles, he oversaw several oncology discovery and development projects including Merck’s immuno-oncology portfolio and the development of Keytruda® (pembrolizumab).

Before joining Schering-Plough, Dr. Hicklin held several positions of increasing responsibility at ImClone Systems (acquired by Eli Lilly), including Vice President of Experimental Therapeutics. His team at ImClone supported the development and FDA approval of the cancer treatment Erbitux® (cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), Portrazza® (necitumumab), Lartruvo® (olaratumab), and other agents that were acquired by Eli Lilly.

Dr. Hicklin holds an M.S. and Ph.D. in Immunology from New York Medical College where he trained with Dr. Soldano Ferrone, and a B.S. from the University of Iowa.

Cynthia Seidel-Dugan, Ph.D.
Chief Scientific Officer
Cynthia Seidel-Dugan, Ph.D.
Chief Scientific Officer

Dr. Cindy Seidel-Dugan is a proficient drug discovery scientist with broad experience in small and large biotech and major pharmaceutical companies. Dr. Seidel-Dugan was a member of the original team of Potenza Therapeutics, rising from Vice President to Senior Vice President of Research and ultimately CSO prior to the company’s acquisition by Astellas Pharma in 2018. She also contributed in the start-up of Tizona Therapeutics and Trieza Therapeutics.

Previously, Dr. Seidel-Dugan served as Vice President, Biology for CoStim Pharmaceuticals where she built a pipeline of therapeutic antibodies targeting immunologic costimulatory receptors, forming the basis for the company’s acquisition by Novartis in 2014.

Early in her career, Dr. Seidel-Dugan built a strong reputation as a research leader and developer of small- and large-molecule drugs over two decades at Ariad Pharmaceuticals, Exelixis Pharmaceuticals, Schering-Plough Research Institute, and (upon merger) Merck Research Laboratories.

Dr. Seidel-Dugan earned a B.S. in Biology from the College of William and Mary and holds a Ph.D. in Microbiology and Molecular Biology from the University of Pennsylvania. She also completed a postdoctoral fellowship with Dr. Joan Brugge at the University of Pennsylvania.

Reid Leonard, Ph.D.
Chief Operating Officer
Reid Leonard, Ph.D.
Chief Operating Officer

Dr. Reid Leonard brings with him a wide array of experience in company formation, drug discovery, business development, and venture capital, having participated in the start-up of several other venture-backed companies: Potenza Therapeutics, Tizona Therapeutics, Trieza Therapeutics, and Twentyeight-Seven, Inc.

Dr. Leonard began his career with Merck & Co., where he served the company for over 25 years. Initially, he carried out discovery research on ion-channel and GPCR targets before moving into business development and licensing. In his later years at Merck, he was instrumental in the formation of the Merck Research Labs Venture Fund. Dr. Leonard retired from Merck as Managing Director of MRL Ventures and Executive Director in Business Development.

Dr. Leonard graduated from Brandeis University with an A.B. in Biology and Psychology, holds a Ph.D. in Biology from Purdue University, and completed a postdoctoral fellowship in molecular pharmacology at Caltech with Profs. Henry Lester and Norman Davidson.

Ellen Lubman, M.B.A.
Chief Business Officer
Ellen Lubman, M.B.A.
Chief Business Officer

Ms. Ellen Lubman brings more than 20 years of biopharmaceutical business and financial industry experience to Werewolf Therapeutics, including global partnering, asset sourcing and acquisition, financial structuring and leading early-stage company operations, fundraising and board governance. She recently served as the Chief Business Officer at Impel NeuroPharma, Inc.

Prior to Impel, she was the Vice President of External Science & Innovation at Allergan, where, through two mergers from Forest Labs and Actavis, she was responsible for strategic expansion of the company’s diverse pipeline of therapeutics in a variety of disease areas. Ms. Lubman has held numerous executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank, and Abbott Labs. Ms. Lubman frequently advises emerging companies on business development strategy and fundraising. She serves on the Board of Directors of GeneCentric Therapeutics and IntrepidaBio, as well as the Advisory Board of TMRW.org. Ms. Lubman also currently serves on the Scientific Advisory Board of the Daedalus Innovation Fund of Weill-Cornell and Board of Directors of Gilda’s Club of NYC.

Ms. Lubman earned her M.B.A. from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College.

Randi Isaacs, M.D.
Chief Medical Officer
Randi Isaacs, M.D.
Chief Medical Officer

Dr. Randi Isaacs is a veteran hematologist and oncologist focused on discovery and development of novel therapeutic approaches in oncology, specializing in immunotherapy, biologic agents, and cell therapies for the treatment of solid tumors and hematologic malignancies. She has devoted her career to bringing new therapeutics to cancer patients to improve clinical outcomes and has made contributions to several successfully registered drugs.

Dr. Isaacs has more than 20 years’ experience in clinical and translational oncology drug development, most recently as the Executive Director and Clinical Site Head of Translational Clinical Oncology at the Novartis Institutes for Biomedical Research (NIBR). She previously held executive leadership roles in oncology and clinical development at Merck, Schering Plough, and Sandoz, where she led projects in all phases of clinical research and supported business development and licensing.

Prior to transitioning to biopharma, Dr. Isaacs held various academic appointments including Assistant Professor of Medicine in the Division of Hematology/Oncology at the State University of New York Health Sciences Center and Clinical Assistant Professor of Hematology/Oncology at the University of Medicine and Dentistry of New Jersey.

Dr. Isaacs earned her B.A. in Chemistry from Wellesley College and holds an M.D. from Dartmouth Medical School. She completed her residency and postdoctoral training at the University of California San Francisco and the Memorial Sloan-Kettering Cancer Center respectively.

Tim Trost
Chief Financial Officer
Tim Trost
Chief Financial Officer

Mr. Trost joined us in February 2021 as Chief Financial Officer. Previously, he served as Chief Financial Officer of Asklepios BioPharmaceutical, Inc. (AskBio), a biotechnology company, from May 2020 until it was acquired by Bayer AG in October 2020.

Prior to joining AskBio, Mr. Trost served as Senior Vice President, Chief Financial Officer, of Chimerix, Inc. (NASDAQ: CMRX), a biopharmaceutical company, from March 2011. Previous to joining Chimerix, from July 2002 he served as Vice President and Chief Financial Officer at Argos Therapeutics, Inc., a venture-backed immunotherapy company. Prior to this, Mr. Trost served as Senior Vice President and Chief Financial Officer at InteCardia, Inc., a venture-backed cardiac imaging company that was acquired by Syncor International Corporation; and as Executive Vice President and Chief Financial Officer of Coastal Physician Group, Inc. (NYSE: DR), a contract provider of emergency room physicians.

Mr. Trost began his professional career with PwC, last serving as a Senior Manager in the Research Triangle practice.

Mr. Trost holds a B.S. in accounting from the University of Illinois at Urbana-Champaign and is a Certified Public Accountant.

Chulani Karunatilake, Ph.D.
Chief Technology Officer
Chulani Karunatilake, Ph.D.
Chief Technology Officer

Dr. Chulani Karunatilake brings more than 30 years of experience in the biopharmaceutical industry as well as Chemistry and Manufacturing Controls (CMC) process and strategy development to Werewolf Therapeutics. Previously, Dr. Karunatilake served as Senior Vice President of Technical Operations for Maverick Therapeutics (acquired by Takeda), where he was responsible for all aspects of CMC.

Prior to Maverick, Dr. Karunatilake was Senior Vice President of Biologics CMC and initially Vice President of Pharmaceutical Development and Manufacturing at Nektar Therapeutics. He has also held numerous leadership positions at Amgen, Chiron/Novartis, Genentech, and Eli Lilly.

Dr. Karunatilake earned his Ph.D. in Chemistry/Biochemistry from the University of Illinois and holds a B.S. in Chemistry from the University of Colombo in Sri Lanka.

Andres Salmeron, Ph.D.
Vice President, Immunology
Andres Salmeron, Ph.D.
Vice President, Immunology

Dr. Andres Salmeron is a trained immunologist with expertise in immuno-oncology and inflammation. He has 20 years of experience in small-molecule and biologics drug discovery in both the pharmaceutical and biotechnology industries. Most recently, Dr. Salmeron served as Senior Director of Immunology at Potenza Therapeutics until its acquisition by Astellas Pharmaceuticals in 2018. Prior to Potenza, he worked as a scientist/manager at Constellation Pharmaceuticals and Abbott Laboratories.

Dr. Salmeron is a graduate of the Universidad Autonoma in Madrid, Spain with a B.S. in Biochemistry and Molecular Biology and a Ph.D. in Immunology. He continued his training as a postdoctoral fellow at the National Institute for Medical Research in Mill Hill, London.

William Winston, Ph.D.
Vice President, Research
William Winston, Ph.D.
Vice President, Research

Dr. Bill Winston is an expert protein engineer with deep experience in the design, discovery, and preclinical development of therapeutic antibody treatments. Most recently, Dr. Winston served as Senior Director, then Vice President of Antibody Development at Potenza Therapeutics. With Potenza, he led both internal and external efforts to identify and, in partnership with Astellas, manage the contract manufacturing of a portfolio of three monoclonal antibodies that all successfully achieved IND clearances prior to the Company’s acquisition by Astellas Pharmaceuticals in 2018. Before joining Potenza, Dr. Winston was a key discovery scientist at AVEO Oncology.

Dr. Winston is a graduate of the Massachusetts Institute of Technology where he earned a B.S. in Biology, and he holds a Ph.D. in Biology from Harvard.

Philipp Steiner, Ph.D.
Vice President, Pharmacology
Philipp Steiner, Ph.D.
Vice President, Pharmacology

Dr. Philipp Steiner is an experienced pharmacologist who has led small molecule, antibody, and oncolytic virus programs targeting receptor tyrosine kinases and immune-oncology (I/O) checkpoints. Before joining Werewolf, Dr. Steiner served as Sr. Director at Potenza Therapeutics supporting a portfolio of I/O antibody programs from discovery to regulatory filings until its successful acquisition by Astellas Pharma. In parallel, he led immuno-modulatory oncolytic virus efforts at Trieza Therapeutics. Prior to Potenza, Dr. Steiner held managerial positions with increasing responsibilities at CoStim Pharmaceuticals, MedImmune, ImClone and Millennium.

Dr. Steiner graduated from the University of Basel, Switzerland, with a Ph.D in Biochemistry. He obtained additional training as a postdoctoral fellow in human tumor biology from the Whitehead Institute at MIT.

Anjili Mathur
Senior Director, Portfolio Strategy
Anjili Mathur
Senior Director, Portfolio Strategy

Ms. Anjili Mathur is a certified project manager (CPM) and an experienced cancer research scientist with over 15 years in the Biotech and Pharmaceutical industry. She has held various roles spanning discovery research, marketing, market access, portfolio strategy and project management. Most recently, Ms. Mathur led AstraZeneca’s U.S. Oncology Precision Medicine marketing efforts supporting the launch of IMFINZI®. Prior to AstraZeneca, Ms. Mathur worked at Merck Research Laboratories where she oversaw strategic portfolio operations for oncology discovery programs and at Curis as a research scientist. She completed her graduate work at Upstate Medical University in Pharmacology and her undergraduate work in Biology at McMaster University in Canada.

Scientific Advisory Board

Michael Atkins, M.D.
Michael Atkins, M.D.

Dr. Atkins is an internationally recognized leader in translational and clinical research for more than 30 years, working in melanoma, kidney cancer, and cancer immunotherapy. He began his career at Tufts Medical Center before moving to Beth Israel Deaconess Medical Center where he was appointed Professor at Harvard Medical School. There, he served as leader of the Biologic Therapy and Cutaneous Oncology Programs at Beth Israel Deaconess Medical Center, Co-PI of the Harvard Skin Cancer SPORE, leader of the Dana Farber Harvard Cancer Center Kidney Cancer Program, and Director of the Kidney Cancer SPORE.

In 2012, Dr. Atkins was named the Deputy Director of the Georgetown Lombardi Comprehensive Cancer Center and William M. Scholl Professor and Vice Chair of the Department of Oncology. His research interests include immunotherapy, anti-angiogenic therapy, molecularly targeted therapy, and predictive biomarker development most notably in melanoma and kidney cancer. He leads the Lombardi Immunotherapy Initiative and co-leads the Melanoma Disease Group within the MedStar Georgetown Cancer Institute. He has published more than 450 original research and review articles, as well as three books, and has lectured extensively on these topics.

He is past president of the Society for Immunotherapy of Cancer (SITC) and past member of the NCI Recombinant DNA Advisory Committee and the ASCO Nominating Committee. Dr. Atkins is Chair of the Medical Advisory Panel for the Melanoma Research Alliance, and co-chair of the Scientific Advisory Committee and Board member for the Melanoma Research Foundation.

Charles Craik, Ph.D.
Charles Craik, Ph.D.

Charles S. Craik is a Professor at UCSF in the Department of Pharmaceutical Chemistry and co-director of the Experimental Therapeutics program in the Helen Diller Family Comprehensive Cancer Center. He is also the founder and co-director of the Chemistry and Chemical Biology Graduate Program. His research interests focus on defining the roles and the mechanisms of enzymes and other challenging proteins in complex biological processes and on developing technologies to facilitate these studies. Current research in the Craik lab is on the chemical biology of post translational modifying enzymes, receptors and membrane transporters. A particular emphasis of his work is on identifying the roles and regulating the activity of proteases and degradative enzyme complexes associated with infectious diseases, neurodegenerative diseases and cancer. He is also developing novel methods to biophysically characterize challenging proteins as well as their complexes. These studies coupled with his global substrate profiling, antibody engineering and noninvasive imaging efforts are providing a better understanding of both the chemical make-up and the biological importance of these critical proteins to aid in the rapid detection, monitoring and control of disease. Craik a founder of Catalyst Biosciences, a Fellow of the American Association for the Advancement of Science (AAAS), the National Academy of Inventors (NAI), the American Academy of Arts and Sciences and the 2016 awardee of the Emil Kaiser Award by the Protein Society.

Vijay K. Kuchroo, D.V.M., Ph.D.
Vijay K. Kuchroo, D.V.M., Ph.D.

Dr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, Boston, and Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. Vijay Kuchroo is also an associate member of the Broad Institute and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. His major research interests include autoimmune diseases – particularly the role of co-stimulation – the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, and cell surface molecules and regulatory factors that regulate induction of T cell tolerance and dysfunction. His laboratory has made several transgenic mice that serve as animal models for human multiple sclerosis.  Dr. Kuchroo first described the inhibitory receptor TIM-3, which is being exploited as a target for cancer immunotherapy.  He was first to describe the development of highly pathogenic Th17 cells, which has been shown to induce multiple different autoimmune diseases in humans. He has published over 325 original research papers in the filed of Immunology and a paper describing development of Th17 authored by Dr. Kuchroo has been one of the highest cited papers in Immunology.

Dr. Kuchroo came to the United States in 1985 and was at the National Institutes of Health, Bethesda as Fogarty International Fellow for a year before joining the department of pathology at Harvard Medical School as a research fellow. He later joined the Center for Neurologic Diseases at Brigham and Women’s Hospital as a faculty member in 1992.

He obtained his degree in Veterinary Medicine from the College of veterinary medicine, Hisar, India. Subsequently, he specialized in pathology at the University of Queensland, Brisbane (Australia) where he obtained a Ph.D. in 1985. He received the Fred Z. Eager Research prize and medal for his Ph.D. research work at the University of Queensland. Based on his contributions, he was awarded the Javits Neuroscience Award by the National Institutes of Health in 2002 and the Ranbaxy prize in Medical Research from the Ranbaxy Science Foundation in 2011. He was named Distinguished Eberly lecturer in 2014 and obtained Nobel Laureate Peter Doherty lecture/prize in 2014.

Dr. Kuchroo has 25 patents and has founded 6 different biotech companies.  He also serves on the scientific advisory boards of a number of big pharmaceutical companies including Pfizer, Novartis, Sanofi/Genzyme and Glaxo-Smith-Klein (GSK).

Dario A. Vignali, Ph.D.
Dario A. Vignali, Ph.D.

Dr. Dario A. Vignali is the Frank Dixon Chair in Cancer Immunology, Vice Chair and Professor of Immunology in the Immunology Department, University of Pittsburgh School of Medicine. He is also Leader of the Cancer Immunology and Immunotherapy Program and co-Director of the Tumor Microenvironment Center in the UPMC Hillman Cancer Center. His research focuses on molecular and cellular aspects of negative regulatory immune mechanisms including regulatory T cells, inhibitory receptors, and inhibitory cytokines. His lab was instrumental in uncovering the role of Lag3 in mouse models of cancer, tolerance, autoimmunity and immune regulation.

Dr. Vignali’s lab discovered the inhibitory cytokine IL35 and the Nrp1:Sema4a axis, which are key regulators of intratumoral Treg stability and function. His current research also uses extensive use of transcriptional analysis, especially using single cell RNAseq. The majority of his work focuses on analysis of these pathways in murine models of cancer and numerous human tumors.

Dario also studies regulatory mechanisms in autoimmunity and type 1 diabetes. He has published more than 170 papers with over 33 as senior or co-author in high impact journals, including Nature, Cell, Science, Nature Immunology, Nature Biotechnology, Nature Methods, Immunity, Science Immunology and EMBO.

K. Dane Wittrup, Ph.D.
K. Dane Wittrup, Ph.D.

Dr. K. Dane Wittrup is the C.P. Dubbs Professor of Chemical Engineering and Biological Engineering at MIT. Dr. Wittrup was elected to the National Academy of Engineering in 2012, elected as a Fellow of the American Association for the Advancement of Science in 2011, and serves as a fellow of the American Institute of Biomedical Engineers. He is also co-founder and Scientific Advisory Board Chairman at Adimab.

Previously, Dr. Wittrup served as an Associate Director of MIT’s Koch Institute until 2017 and as the J. W. Westwater Professor of Chemical Engineering, Biophysics, and Bioengineering at the University of Illinois at Urbana-Champaign. Prior to that, he worked as a postdoctoral research associate in Amgen’s Yeast Molecular Biology Group. He earned a Ph.D. and M.S. in Chemical Engineering from the California Institute of Technology and a B.S. in Chemical Engineering from the University of New Mexico.

Board of Directors

Luke Evnin, Ph.D.
MPM Capital
Luke Evnin, Ph.D.
MPM Capital

Dr. Luke Evnin is Managing Director of MPM Capital, an investment firm he co-founded in 1997.

MPM remains dedicated to founding and investing in life sciences companies that seek to translate scientific innovations into clinical outcomes and currently is investing across several funds and over $2.5 billion of committed capital. Over the past seven years, as a component of his MPM activities, Luke has been a co-founder and served as chairman of the board for seven of MPM portfolio companies including Amphivena Therapeutics, Blade Therapeutics, Harpoon Therapeutics, Maverick Therapeutics, Potenza Therapeutics, Tizona Therapeutics and Werewolf Therapeutics.  He has contributed as a co-inventor in Werewolf and in several other of these companies as well as MPM portfolio company Oncorus. And, from October 2017 to June 2019, Dr. Evnin served as the interim Chief Executive Officer of Werewolf Therapeutics, Inc., where he continues to serves as chairman of its board of directors. In addition, he currently serves, on behalf of MPM Capital, as a director for eight other private companies. He was the lead investor and served on the boards of several of MPM’s most successful investments including CoStim, Idun Pharmaceuticals, and Pacira.

Dr. Evnin has also served on the board of directors of many other public and private companies over his 28-year venture capital career, including past service as a director of Syndax Pharmaceuticals, Inc., EnteroMedics Inc. (now known as ReShape Lifesciences Inc.), Epix Medical, Inc., Intercell AG, Metabasis Therapeutics, Inc. (acquired by Ligand Pharmaceuticals, Inc.), Oscient Pharmaceuticals Corp., Pacira Pharmaceuticals Inc., Restore Medical, Inc. (acquired by Medtronic, Inc.), Sonic Innovations, Inc. and Signal Pharmaceuticals, Inc. (acquired by Celgene Corporation).

Dr. Evnin also serves as chairman of the board of directors of the Scleroderma Research Foundation, a not-for-profit entity where he has contributed for over 20 years. In recognition of MPM’s novel work, Luke was a recipient of the 2017 Global Oncology Visionary Award.

Prior to co-founding MPM, he honed his skills as a venture capitalist at Accel Partners. Dr. Evnin holds a Ph.D. in Biochemistry (1990) from the University of California at San Francisco (UCSF).

Sakae Asanuma, CFA
Taiho Ventures
Sakae Asanuma, CFA
Taiho Ventures

Mr. Sakae Asanuma established Taiho Ventures as the founding President in 2016. Prior to this position, he was President and CEO at Astellas Venture Management and U.S. Head of Astellas Innovation Management from 2011–2015. Before joining Astellas, he worked for Yasuda Enterprise, a Japan/US-based VC firm from 2000–2011. He has invested in more than 50 biotech companies since 2000 and half of them achieved IPOs or M&As. During his tenure at Taiho and Astellas, Mr. Asanuma closed dozens of research collaborations with academia and biotech ventures, including several build-to-buy or spin-out deals.

Meeta Chatterjee, Ph.D.
SVP, Global Business Development, Legend Biotech Corporation
Meeta Chatterjee, Ph.D.
SVP, Global Business Development, Legend Biotech Corporation

Dr. Meeta Chatterjee has served as the Senior Vice President of Global Business Development of Legend Biotech Corporation since March, 2019. She was previously Head of Strategy, Transactions, and Operations within the Business Development and Licensing (BD&L) group at Merck Research Labs. Dr. Chatterjee oversaw discovery and late-stage transactions worldwide, as well as early-stage transactions in key geographies. She also was responsible for Merck’s BD&L governance, oversight, and control as well as out-licensing efforts.

Dr. Chatterjee has over 30 years of broad strategic and operational experience in pharmaceutical research and development, mergers and acquisition evaluation, in-licensing, and externalization activities. Over the course of her extensive career, Dr. Chatterjee has led or contributed to a number of transactions or collaborations, has led research efforts in the areas of hypertension, atherosclerosis, and obesity, and was an integral contributor to the discovery of ZETIA® and ZONTIVITY®.

Dr. Chatterjee received her undergraduate education at St. Xavier’s University in Ahmedabad, India, and Rutgers University (B.A., Hons Physics). She received her Doctor of Philosophy in Physiology from Rutgers University and completed a postdoctoral fellowship in the Department of Physiology at the University of Virginia School of Medicine. Dr. Chatterjee is also active in industry and licensing focused organizations.

Derek DiRocco, Ph.D.
RA Capital Management
Derek DiRocco, Ph.D.
RA Capital Management

Derek DiRocco is a Partner at RA Capital Management. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, and CANbridge. Previously, Derek covered solid tumor oncology landscapes. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. He conducted his postdoctoral research at Brigham and Women’s Hospital/Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis.

Dan Hicklin, Ph.D.
President and Chief Executive Officer, Werewolf Therapeutics
Dan Hicklin, Ph.D.
President and Chief Executive Officer, Werewolf Therapeutics

Dr. Dan Hicklin is an accomplished cancer researcher and biopharmaceutical executive with over three decades of oncology drug development experience. Currently, Dr. Hicklin holds a number of executive positions:

  • Executive Partner at MPM Capital
  • Founder and CEO of Werewolf Therapeutics
  • President of Trieza Therapeutics
  • Board member of Tizona Therapeutics and Maverick Therapeutics

Prior to his current positions, he founded Potenza Therapeutics (acquired by Astellas Pharma) where he was President and CEO, served as President and CSO of CoStim Pharmaceuticals (acquired by Novartis), and was on the board of directors of Harpoon Therapeutics and the scientific advisory board of Oncorus.

Earlier in his career, Dr. Hicklin held several positions at Merck Research Laboratories (formerly the Schering-Plough Research Institute), including leading their Biologics Strategy for Oncology and the Immuno-Modulation Discovery team. In these roles, he oversaw several oncology discovery and development projects including Merck’s immuno-oncology portfolio and the development of Keytruda® (pembrolizumab).

Before joining Schering-Plough, Dr. Hicklin held several positions of increasing responsibility at ImClone Systems (acquired by Eli Lilly), including Vice President of Experimental Therapeutics. His team at ImClone supported the development and FDA approval of the cancer treatment Erbitux® (cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), Portrazza® (necitumumab), Lartruvo® (olaratumab), and other agents that were acquired by Eli Lilly.

Dr. Hicklin holds an M.S. and Ph.D. in Immunology from New York Medical College where he trained with Dr. Soldano Ferrone, and a B.S. from the University of Iowa.

Alon Lazarus, Ph.D.
Arkin Bio Ventures
Alon Lazarus, Ph.D.
Arkin Bio Ventures

Dr. Alon Lazarus is a Biotech Investment Manager for Arkin Holdings’ Pharma Division. He is a member of the Board of several of its pharmaceutical companies, including Keros Therapeutics, Lutris Pharma, Redpin Therapeutics, and Explore Bio.

Prior to joining Arkin, Dr. Lazarus worked for the Healthcare Business Development Department of Yissum—the Research & Development arm of the Hebrew University and as an analyst for the University’s Integra Holdings. Alon earned both a Ph.D. in Molecular Biology and an MBA from the Hebrew University of Jerusalem in Israel.

Briggs W. Morrison, M.D.
CEO, Syndax Pharmaceuticals and Executive Partner, MPM Capital
Briggs W. Morrison, M.D.
CEO, Syndax Pharmaceuticals and Executive Partner, MPM Capital

Dr. Briggs W. Morrison is the CEO and a Board Director of Syndax Pharmaceuticals, and Executive Partner at MPM Capital. He serves on the boards of several MPM portfolio companies and is an investment committee member of MPM’s impact collaboration with global financial services firm UBS, that is a public/private crossover vehicle managed by MPM.

Prior to joining Syndax and MPM, Briggs served as Chief Medical Officer and Executive Vice President for Global Medicines Development at AstraZeneca. His career also includes distinguished roles at Pfizer and Merck. As Head of Global Medicines Development at AstraZeneca, he oversaw all clinical development functions and late-stage clinical development projects. As Head of Clinical Development at Pfizer, he oversaw Phase 1-3 development and operations for all therapeutic areas before being appointed the Head of Development, Medical Affairs, Safety and Regulatory Affairs for all Pfizer human health businesses. Briggs has overseen the development of numerous biopharmaceutical products in multiple therapeutic areas. He was also the former Chairman of Transcelerate BioPharma, an industry-funded company charged with improving aspects of clinical trials.

Briggs earned his M.D. from the University of Connecticut and completed his training in Internal Medicine at Massachusetts General Hospital and in Medical Oncology at the Dana-Farber Cancer Institute. He also completed a post-doctoral research fellowship in the Department of Genetics at Harvard Medical School and additional post-doctoral work at the Dana-Farber Cancer Institute. He received his B.S. in Biology from Georgetown University.

Mike Sherman
Chief Executive Officer, Chimerix
Mike Sherman
Chief Executive Officer, Chimerix

Mr. Sherman has more than 30 years’ experience advancing therapeutics to commercial launch and driving companies to successful operations and strategic transactions in the biotechnology and medical technology industries. He is currently Chief Executive Officer of Chimerix.

Before joining Chimerix, he served as Chief Executive Officer of Endocyte, Inc. and led it to its $2.1 billion acquisition by Novartis in 2018. Mr. Sherman joined Endocyte in 2006 and served as its Chief Financial Officer and Chief Operating Officer prior to becoming Chief Executive Officer in 2016. Mr. Sherman repositioned the company by re-prioritizing the pipeline, acquiring an external asset, and aggressively executing a phase 3 regulatory and clinical strategy, and was instrumental in Endocyte’s IPO and four subsequent financings. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, which was acquired by Boston Scientific Corporation.

Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, graduating as a Tuck Scholar. Mr. Sherman currently serves on the Board of Trustees for the Children’s Museum of Indianapolis as past chairman. He also served on the Boards of Directors at Biospecifics Technologies, Inc. until its acquisition by Endo Pharmaceuticals and Mead Johnson Nutrition until its acquisition by Reckitt Benckiser.